Holen Sie sich die Stockscreener-App
0.6926
4.18%
0.0278
Handel nachbörslich:
.67
-0.0226
-3.26%
Schlusskurs vom Vortag:
$0.6648
Offen:
$0.693
24-Stunden-Volumen:
160.02K
Relative Volume:
0.78
Marktkapitalisierung:
$9.43M
Einnahmen:
$17.44M
Nettoeinkommen (Verlust:
$-21.23M
KGV:
-0.3097
EPS:
-2.2361
Netto-Cashflow:
$-17.60M
1W Leistung:
-6.97%
1M Leistung:
-42.76%
6M Leistung:
-73.26%
1J Leistung:
-76.91%
1-Tages-Spanne:
$0.6616
$0.70
1-Wochen-Bereich:
$0.6506
$0.799
52-Wochen-Spanne:
$0.6506
$7.95
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Firmenname
Vivos Therapeutics Inc
Sektor
Branche
Telefon
(866)908-4867
Adresse
7921 SOUTHPARK PLAZA,, LITTLETON
Compare VVOS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
0.6926 | 9.05M | 17.44M | -21.23M | -17.60M | -2.2361 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Vivos Therapeutics Inc Aktie (VVOS) Neueste Nachrichten
[EFFECT] Vivos Therapeutics, Inc. SEC Filing - Stock Titan
Vivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potential - MSN
Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges - TipRanks
3.96M warrant shares registered by Vivos (VVOS) for resale; $2.09 strike - Stock Titan
VVOS Forecast, Price Target & Analyst Ratings | VIVOS THERAPEUTICS INC (NASDAQ:VVOS) - ChartMill
Vivos Therapeutics (VVOS) price target decreased by 51.67% to 2.47 - MSN
Broadcom, Vivos Therapeutics and 3 stocks to watch heading into Monday - MSN
Vivos Therapeutics (NASDAQ: VVOS) registers 3.96M warrant-linked shares for resale - Stock Titan
VVOS Should I Buy - Intellectia AI
Vivos Therapeutics receives Nasdaq notice for stockholders’ equity deficiency - Investing.com
Vivos Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Equity shortfall puts Vivos Therapeutics (NASDAQ: VVOS) at Nasdaq delisting risk - Stock Titan
Qorvo To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Vivos Reports 16% Revenue Increase in 2025 Following Business Model Shift - Sleep Review
Vivos Therapeutics stock price target lowered to $2.50 by H.C. Wainwright - Investing.com Australia
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM ESTShow #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Viv - ACCESS Newswire
Analysts Conflicted on These Healthcare Names: Vivos Therapeutics (VVOS), Certara (CERT) and Option Care Health (OPCH) - The Globe and Mail
H.C. Wainwright Maintains Vivos Therapeutics(VVOS.US) With Buy Rating, Cuts Target Price to $2.5 - 富途牛牛
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2025 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics (VVOS) Stock: Why Cash Position (Freefalls) 2026-04-16Popular Trader Picks - Cổng thông tin điện tử tỉnh Lào Cai
Vivos Therapeutics Balances Growth Hopes With Cash Strain - TipRanks
Vivos Therapeutics Reports Full Year 2025 Financial Results - ADVFN
Vivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... By GuruFocus - Investing.com Canada
Vivos Therapeutics Reports 16% Revenue Growth in 2025, Advances Sleep Center Integration and Eyes Cash Flow Positive Operations - Minichart
Vivos Therapeutics Pivots to Medical-Provider Focused Model with Sleep Center of Nevada Acquisition to Expand Sleep Apnea Solutions 91 - Minichart
Earnings call transcript: vivos beats Q4 2025 earnings expectations - Investing.com UK
VVOS: 2025 revenue rose 16% as SCN integration fueled growth, with further expansion planned for 2026 - TradingView
Earnings Call Summary | Vivos Therapeutics(VVOS.US) Q4 2025 Earnings Conference - 富途牛牛
VVOS: 2025 revenue up 16% from SCN integration, with strong growth outlook as new model scales - TradingView
Earnings call transcript: vivos beats Q4 2025 earnings expectations By Investing.com - Investing.com India
Vivos Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Vivos Therapeutics (NASDAQ: VVOS) grows 2025 revenue as net loss widens - Stock Titan
Vivos Therapeutics 2025 10-K: $17.44M Revenue, $(2.07) EPS - TradingView
Vivos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Vivos Therapeutics (NASDAQ: VVOS) details SCN deal and new sleep-center strategy - Stock Titan
Vivos grows on sleep apnea services, but operating loss hits $19.9M - Stock Titan
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results - National Today
Vivos Therapeutics, Inc. to Release Full Year 2025 Financial Results and Conduct Conference Call on April 15, 2026 - Quiver Quantitative
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call - The Manila Times
Vivos investors get 2025 results and strategy update at 5 p.m. ET - Stock Titan
Vivos Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Vivos Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma (IGC), Vivos Therapeutics (VVOS), Acurx Pharmaceuticals (ACXP), and Equinox Gold (EQX) - Scott Coop
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ - ACCESS Newswire
Finanzdaten der Vivos Therapeutics Inc-Aktie (VVOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):